Home › Funds › BAKER BROS. ADVISORS LP › AKTS

BAKER BROS. ADVISORS LP position in AKTS

AKTIS ONCOLOGY INC · Health Care

BAKER BROS. ADVISORS LP reported holding 996,351 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$32.1M, representing 0.17% of its reported portfolio and ranking #44 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)996.35K sh
Reported value held$32.11M
Portfolio Weight0.17%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's AKTS position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in AKTS in Q1 2026 at 996,351 shares (US$17.8M). The position peaked in Q2 2026 at 996,351 shares, worth US$32.1M. Across 2 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 996,351 shares valued at US$32.1M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 996.35K $17.82M New
Q2 2026 996.35K $32.11M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AKTS and 13F data

AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AKTS

All AKTS fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held AKTS?

BAKER BROS. ADVISORS LP has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is BAKER BROS. ADVISORS LP's current position in AKTS?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 996.35K shares of AKTS (AKTIS ONCOLOGY INC), valued at $32.11M, representing 0.17% of its reported portfolio and ranking #44.

Has BAKER BROS. ADVISORS LP been buying or selling AKTS?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in AKTS. The position peaked in Q2 2026 at 996.35K shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 121 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.